{"id":391166,"date":"2016-04-06T00:00:00","date_gmt":"2016-04-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0006-2016-biopharma-post-herpetic-neuralgia-unmet-need-us-eu-2016\/"},"modified":"2026-03-31T09:02:23","modified_gmt":"2026-03-31T09:02:23","slug":"unnecg0006-2016-biopharma-post-herpetic-neuralgia-unmet-need-us-eu-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0006-2016-biopharma-post-herpetic-neuralgia-unmet-need-us-eu-2016\/","title":{"rendered":"Post Herpetic Neuralgia | Unmet Need | US\/EU | 2016"},"content":{"rendered":"<p>Postherpetic neuralgia (PHN) has served\u2014and continues to serve\u2014as a gateway indication into the lucrative neuropathic pain (NP) therapy market. Drugs such as Pfizer\u2019s Lyrica (pregabalin), gabapentin (Pfizer\u2019s Neurontin, generics), and the 5% lidocaine patch (Endo\/Gr\u00fcnenthal\u2019s Lidoderm\/Versatis, generics) all capitalized on their approvals for PHN in the United States and Europe to achieve wider commercial success in the treatment of other forms of NP, such as neuropathic back pain and postsurgical\/post-trauma NP. Despite the availability of multiple generic analgesics and well-established treatments for PHN, the substantial percentage of patients refractory to treatment, the high rate of polypharmacy, and the large unmet need associated with pain treatment make PHN\u2014and NP overall\u2014an area of commercial opportunity.<\/p>\n","protected":false},"template":"","class_list":["post-391166","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neuropathic-pain","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391166\/revisions"}],"predecessor-version":[{"id":394289,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391166\/revisions\/394289"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}